Epilepsy Epidiolex denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for epilepsy epidiolex are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Epidiolex for Medical Necessity — and How to Build a Winning Appeal

Epidiolex (cannabidiol) is an FDA-approved anti-seizure medication for certain rare, severe epilepsy syndromes. Cigna's medical-necessity denial means the plan's reviewer concluded that the submitted clinical information did not satisfy the criteria in Cigna's coverage policy for Epidiolex. This does not mean the medication is not appropriate — it means the documentation submitted with the prior authorization did not clearly map to every requirement Cigna uses. The appeal is an opportunity to close that gap.

## Why This Denial Is Appealable

Medical-necessity denials for Epidiolex are frequently overturned when the treating neurologist provides a complete, criterion-by-criterion response to Cigna's policy. The most common reasons for initial denial are: insufficient documentation of prior anti-seizure medications tried and failed, incomplete seizure frequency data, or a missing specialist attestation. All of these gaps can be cured on appeal.

## Your Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 guarantee a full-and-fair internal review. Submit your appeal within the deadline stated in the denial letter (typically 180 days).
• External review: If the internal appeal is denied, you have approximately four months to request independent external review. An IRO reviewer with neurology credentials will independently assess the clinical record.
• Expedited option: If the patient is experiencing frequent or severe breakthrough seizures, request expedited review for a 72-hour resolution.

## Documentation to Gather

1. Confirmed diagnosis documentation: EEG reports, MRI brain imaging, genetic testing results (if applicable), and specialist clinic notes confirming the specific epilepsy syndrome covered under Cigna's policy. 2. Prior anti-seizure medication history: A comprehensive, chronological list of every ASM tried — including drug name, dates of use, doses (from the chart), and documented reason for discontinuation (lack of efficacy, adverse effect, or both). 3. Seizure frequency and severity: A seizure diary or summary from the chart covering recent months, showing the type, frequency, and severity of breakthrough events. 4. Clinical severity markers: Notes documenting falls, injuries, hospitalizations, or quality-of-life impact attributable to uncontrolled seizures. 5. Neurologist or epileptologist medical-necessity letter: A detailed letter from the treating specialist explaining the diagnosis, the inadequacy of prior treatments, and why Epidiolex is the appropriate next treatment step — explicitly addressing each of Cigna's listed criteria.

## Criteria-Mapping Structure

Download Cigna's coverage policy for Epidiolex from the Cigna website. List every medical-necessity criterion and map each to your clinical record:

| Cigna Coverage Criterion | Supporting Clinical Evidence | |---|---| | Confirmed diagnosis of covered syndrome | [EEG report date, genetic test result, specialist note] | | Age or other patient characteristic met | [Documented in chart by treating physician] | | Prior ASMs tried and failed (number and type per policy) | [List with dates and outcomes from chart] | | Prescribing neurologist or epileptologist | [Specialist credentials and letter] | | Ongoing monitoring plan | [Follow-up visit schedule documented in letter] |

Submitting this table as part of your appeal letter makes it straightforward for the reviewer to check each box and significantly increases the probability of approval.